key: cord-0937104-lb5cg801
authors: Wang, Yan; Chen, Lei
title: Lung tissue distribution of drugs as a key factor for COVID‐19 treatment
date: 2020-05-18
journal: Br J Pharmacol
DOI: 10.1111/bph.15102
sha: b13cd15a6983568e61f665efb2906e4bca162553
doc_id: 937104
cord_uid: lb5cg801

nan

update on May 8, 2020). It is impossible to create novel drugs against the coronavirus in a very short time, as it often takes years; therefore, the best strategy is to find new antiviral uses from approved drugs (Harrison, 2020) . Not surprisingly, SARS-CoV-2 shares a highly similar viral genome sequence with SARS-CoV (Wan et al., 2020) , suggesting that the effective treatments for SARS may also work for COVID-19 treatment.

Lopinavir, a protease inhibitor of human immunodeficiency virus type 1 (HIV-1), showed good inhibitory effects on SARS-CoV replication in cell-based assays. In clinical trials, the combination of lopinavir and ritonavir benefited the patients with SARS by reducing the viral loads (Stockman et al., 2006) . Lopinavir has been identified as a main protease inhibitor of SARS-CoV, and approved for inhibiting the SARS-CoV replication (Nukoolkarn et al., 2008) .

Recent docking simulation studies showed that lopinavir can also directly bind to the catalytic pocket of SARS-CoV-2 main protease, indicating its potential to reduce the viral loads in patients with COVID-19 (Alessandro, 2020) . However, in clinical trials, no benefits were observed with lopinavir-ritonavir treatment beyond standard care in patients with COVID-19 (Cao et al., 2020) .

Both SARS-CoV and SARS-CoV-2 can attach to angiotensin-converting enzyme 2 (ACE2) and then enter host cells through ACE2 (Wan et al., 2020) . Given that ACE2 is highly expressed in type II alveolar (AT2) cells in lung , lung becomes a major organ under the coronavirus attack. Notably, ACE2 bound to the SARS-CoV-2 spike protein with ~15 nM affinity, which is ~10-to 20-fold higher than the binding capacity of ACE2 to SARS-CoV spike protein (Wrapp et al., 2020) . It is indicated that SARS-CoV-2 can enter AT2 cells in lung much easier than SARS-CoV. The viral loads of SARS-CoV-2, in turn, might be much higher than viral loads of SARS-CoV in the lung tissue. Therefore, it might be more effective if the anti-SARS-CoV-2 drugs could be distributed to the lung with high priority.

In a previous study, the tissue distribution of isotope-labeled lopinavir was examined in rats.

The peak radioactivity levels in plasma were achieved at 4 h post-administration. Liver (52.24 μg equiv/ml), adrenals (4.80 μg equiv/ml), and thyroid (4.41 μg equiv/ml) exhibited greater radioactivity levels than plasma after 4 hours of oral administration (lopinavir, 10 mg/kg). The lung (1.18 μg equiv/ml) exhibited less radioactivity levels than plasma, indicating that the distribution of lopinavir in the lung tissue is relatively low (Kumar et al., 2004) . We guess the concentration of lopinavir in the lung is too low to inhibit SARS-CoV-2 replication. It might explain why lopinavir did not benefit the patients with COVID-19.

Unlike lopinavir, chloroquine exhibited clinical and virologic benefits in the treatment of COVID-19 patients, including improving lung image findings and reducing the viral loads. In preclinical studies, chloroquine showed strong inhibitory effects on SARS-CoV-2 replication in cell-based assays (EC50 = 1.13 μM) . Although chloroquine was reported to impair the endosome-mediated viral entry, the precise mechanism of action of chloroquine remains unclear. Lung is one of the major target tissues of chloroquine, as evidenced by the tissue distribution studies in rats. After an oral administration of 14 Cchloroquine (20 mg/kg), the concentrations of 14 C-chloroquine in lung tissues were similar in albino and pigmented rats (30.76 ± 0.85 and 34.76 ± 1.56 μg equiv/ml, respectively) (Ono et al., 2003) . In a long-term treatment study (16.8 mg/kg/day, total 32 weeks), the concentrations of chloroquine in lung tissues were 51.7 ± 3.1 and 104 ± 7.0 μg/mg in male and female rats, respectively (McChesney et al., 1967) . Both these pharmacokinetics studies showed that the concentration of chloroquine is high in the lung tissue. We believe that chloroquine can take an advantage of the high volume of the lung distribution to inhibit the viral replication in the lung. Therefore, besides the mechanism of action of antiviral drugs, the lung distributions of drugs should be considered in the COVID-19 treatment.

Together, we propose here that anti-SARS-CoV-2 drug repurposing studies should pay more attentions to the lung tissue distribution of antiviral drugs. Considering the high viral loads in the lung tissue of COVID-19, the low volume of the lung distribution of antiviral drugs might not be sufficient to inhibit the coronavirus replication. Among the anti-SARS-CoV-2 drugs in the clinical trials, chloroquine is likely to be a promising drug that benefit COVID-19 patients because of its high volume of the lung distribution. So far, remdesivir is the most potent inhibitor of SARS-CoV-2 in vitro (EC50 = 0.77 μM) , but lacks of the tissue distribution data in public. Although remdesivir was reported to reduce MERS-CoV viral lung loads in animals (de Wit et al., 2020) , we are eager to see its lung tissue distribution study. It would help to find an appropriate dosing and route of administration of remdesivir. Furthermore, the pharmacodynamic markers also need to be considered in these drug repurposing studies. The high-quality pharmacokinetic and pharmacodynamic (PK/PD) data could monitor biological responses and tell whether these drugs are truly effective or ineffective in the clinical trials.

Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Coronavirus puts drug repurposing on the fast track

Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans

Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors

Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquinerelated radioactivity to melanin in-vivo

SARS: systematic review of treatment effects

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa